AD Pipeline Watch: Aslan Reports “Spectacular Results” in Phase 2 Study of Eblasakimab That Included Some Dupilumab-experienced Patients
Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% achieved a Validated Investigator Global Assessment (vIGA) score of 0 or 1 after 16 weeks compared to 14.3% of patients on placebo, according to positive interim results from […]